Emd Serono Research & Development Institute, Inc.

This early-phase trial tested a new drug called M6223, which blocks a protein called TIGIT that can turn off immune cells. M6223 was given alone or together with another drug, bintrafusp alfa, to 58 people with advanced solid tumors that had stopped responding to standard treatme…

This study followed 22 cancer patients who were already taking bintrafusp alfa in earlier trials, to see how safe it is over the long term and how long they live. Participants continued receiving the drug until it was no longer helping or became available commercially. The main g…

This completed study looked at how well cladribine tablets work in everyday practice for people with relapsing multiple sclerosis (MS) who had a poor response to other oral or infusion treatments. Researchers tracked 291 participants over 24 months, measuring relapse rates and pa…

This study tested an experimental drug called enpatoran in 456 people with lupus, a chronic autoimmune disease. Participants took either a low, medium, or high dose of enpatoran or a placebo for 24 weeks. The goal was to see if the drug safely reduces skin and overall disease act…

This study tested whether a new liquid form of follitropin alfa (a hormone used for fertility) works the same as the standard powder form. Fifty-five healthy men with low testosterone levels were given both versions at different times. The goal was to compare how the drug is abso…